The Control Arc
The Control Arc: Semaglutide, Tirzepatide, and the New Appetite Story
Hunger was never just a test of character. Incretin-based medicines changed the conversation by targeting biological signals—and newer research is asking what comes next.
Key takeaways
- 1.Semaglutide and tirzepatide act on different combinations of hormone receptors.
- 2.Evidence from clinical trials supports specific medicines, not unverified research products.
- 3.Retatrutide adds another receptor target, but more targets do not automatically mean the best choice for an individual.
The opponent gets a name
He can push through a difficult set. He can wake up early. He can keep a promise to himself for weeks.
But the kitchen still becomes a negotiation at night.
The previous Hunger Arc explained why appetite fights back. This chapter goes deeper: what happens when a medicine targets part of that system?
At an appointment, he brings a notebook instead of a list of internet recommendations. His first question is simple: “How do these medicines actually differ?”
One target, two targets, three targets
Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors. Retatrutide is being developed to activate GIP, GLP-1, and glucagon receptors. [1][2]
These pathways participate in metabolic regulation. They are not identical switches, and receptor count is not a complete measure of effectiveness or safety.
The phrase “GLP-3” sometimes appears online around retatrutide. It is informal shorthand, not the name of a third GLP receptor or hormone.
What comparisons can actually tell us
In the randomized SURMOUNT-5 trial, tirzepatide produced greater average reductions in body weight and waist circumference than semaglutide over 72 weeks in adults with obesity without diabetes. [1]
That answers a defined comparison. It does not mean everyone responds the same way, or that the trial identifies the right treatment for a particular reader.
Retatrutide has also produced positive phase 3 results. Lilly’s May 2026 announcement described TRIUMPH-1 in adults with obesity or overweight and a weight-related condition, without diabetes. The drug remained investigational. [2]
Comparing a headline from that study with a headline from another trial is different from comparing medicines directly. Participants, duration, analysis methods, and treatment conditions can change the result.
The story includes tolerability
The character initially wants to hear only about the scale. His clinician redirects the conversation toward the whole experience.
What are the known risks? Which symptoms should prompt a call? What else is he taking? Can he keep eating adequately and training consistently? What will follow-up look like?
Those questions belong in the chapter as much as the outcome graphs do. For example, Lilly’s TRIUMPH-1 announcement reported treatment discontinuations due to adverse events alongside weight outcomes. [2]
An intervention is more than its biggest result.
Less struggle still needs structure
The imagined breakthrough in an anime is often a moment when effort becomes effortless. Real care is more complicated.
A reader whose clinician prescribes an appropriate medicine still needs a workable routine: meals, movement, follow-up, and a way to notice changes. A quieter appetite does not by itself establish adequate nutrition, muscle preservation, or long-term maintenance.
Our character leaves the appointment with fewer assumptions. He understands the pathways better. He also understands why his own care cannot be selected from someone else’s transformation photo.
Science check
Analysis // 08What we know
- Controlled human trials show substantial average weight reductions with specific incretin-based treatments in studied populations.
What remains uncertain
- An individual’s response, and whether findings extend to untested combinations or products.
Power scale · strength of evidence
These labels describe evidence for a defined claim, not product ratings.
- Semaglutide versus tirzepatide in SURMOUNT-5Human clinical evidence
Direct human comparative evidence in adults with obesity without diabetes.
- Retatrutide outcomes in TRIUMPH-1Limited human evidence
Human clinical development evidence; the cited announcement describes an investigational drug.
- Combining research productsNot established
Trials of individual medicines do not establish the benefits or safety of untested combinations.
Research log // 08
- 01 · Before you compare
- Compare population, duration, outcomes, and adverse events before comparing headline percentages.
Limitations
This article does not select a medication, dose, combination, or treatment plan. Research-labelled products are not substitutes for prescribed, trial-tested medicines. The recurring character is fictional and is not a patient testimonial.
Sources
Your next arc starts with better information.
Body composition, metabolic health, training and emerging research—without the hype. Plus occasional updates from our affiliated research business, TPG Bioscience.
Educational information only. This article does not provide medical advice, diagnosis, dosing, or treatment recommendations.
Related articles
The Hunger Arc: Why Appetite Feels Like the Final Boss
Hunger is not a character flaw—it is a regulated biological system that pushes back when you diet. What research shows about appetite hormones, food environment, protein, sleep and stress.
Recomp Report Editorial Team · 30 September 2026
The Plateau Arc: When You're Stronger but the Fat Loss Stops
Why does fat loss slow down even when you're still training? Understand metabolic adaptation, appetite, movement and what newer incretin research actually shows.
Recomp Report Editorial Team · 26 September 2026
The Awakening Arc: When Peptides Enter the Story
The training is familiar. The molecular names are new. Before the next chapter begins, understand what peptides are—and why the same label can describe very different kinds of evidence.
Recomp Report Editorial Team · 11 October 2026